A Phase II, Multicenter, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SCT650C in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Latest Information Update: 01 Dec 2025
At a glance
- Drugs SCT 650C (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Sponsors Sinocelltech
Most Recent Events
- 01 Dec 2025 New trial record